Contact this trialFirst, we need to learn more about you.
PI3K Inhibitor
Copanlisib + Fulvestrant for Hormone Receptor-Positive Cancers
Recruiting1 awardPhase 2
Houston, Texas
This trial looks at whether adding copanlisib to fulvestrant helps people with HR+ solid tumors that contain alterations that activate the PI3K pathway.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service